CD33 and acute myeloid leukemia: Similar observations were made using a CD33 targeting TCB with AML cell lines and primary AML cells showing that enhanced tumor cell killing by the combination of Ven/Aza and TCBs is tumor target independent (Supplementary Fig. 2D–F).